Recombinant Saccharomyces cerevisiae ADP-ribosylation factor-like protein 1 (ARL1)

What is ADP-ribosylation factor-like protein 1 (ARL1) in Saccharomyces cerevisiae?

ARL1 in Saccharomyces cerevisiae is a gene encoding a protein that belongs to the Ras superfamily of small GTP-binding proteins (GTPases). The protein is structurally related (>60% identical) to human, rat, and Drosophila ARL1 proteins . ARL1 is classified as an ARF-like protein, distinguishing it from the highly conserved ADP-ribosylation factors (ARFs). While ARFs share >60% sequence identity and similar biological activities, ARLs like ARL1 are more divergent (40-60% identity) and function in secretory and other cellular pathways . The protein has a molecular weight of approximately 20-24 kDa and exhibits the ability to bind and hydrolyze GTP, similar to other ARF and ARL proteins .

How does yeast ARL1 compare structurally and functionally to ARF proteins?

Despite structural similarities to ARF proteins, yeast ARL1 exhibits several distinct characteristics:

The biochemical differences between ARL1 and ARF proteins suggest distinct functional roles despite their structural relatedness .

Is ARL1 evolutionarily conserved across species?

Yes, ARL1 shows remarkable evolutionary conservation across diverse eukaryotic species. The yeast ARL1 protein shares >60% sequence identity with human, rat, and Drosophila ARL1 proteins . This high degree of conservation suggests fundamental cellular functions that have been preserved throughout eukaryotic evolution. Interestingly, anti-yeast ARL1 antibodies cross-react with human ARLs but not with yeast ARFs, further demonstrating the evolutionary relationship between ARL proteins across species . The conservation extends to functional aspects as well, with both yeast and mammalian ARL1 showing association with the Golgi complex, although the specific roles may vary between organisms .

What are the specific biochemical properties of recombinant Saccharomyces cerevisiae ARL1 protein?

Recombinant Saccharomyces cerevisiae ARL1 protein exhibits several key biochemical properties:

• Nucleotide binding and hydrolysis: The protein can bind and hydrolyze GTP, similar to other G proteins of the Ras superfamily .

• Post-translational modification: The amino terminus of yeast ARL1 is myristoylated, which likely influences its membrane association properties .

• Differential activity from ARFs: Unlike ARF proteins, recombinant yARL1 does not stimulate cholera toxin-catalyzed auto-ADP-ribosylation, highlighting a functional distinction despite structural similarities .

• Immunological properties: yARL1 is not recognized by antibodies against mammalian ARLs or yeast ARFs, suggesting unique epitope characteristics. Conversely, anti-yARL1 antibodies do not cross-react with yeast ARFs but do react with human ARLs .

• Subcellular distribution: On subcellular fractionation, yARL1 is primarily localized to the soluble fraction, similar to yARF1 .

These properties provide important insights into the protein's functional capabilities and suggest methodological approaches for its study in research contexts.

How does the GTP-binding cycle of ARL1 regulate its function in cellular processes?

While the search results don't specifically detail the exact GTP-binding cycle regulation mechanism for ARL1, we can infer from its classification as a GTPase that ARL1 likely functions as a molecular switch through GTP binding and hydrolysis . This cycling between GTP-bound (active) and GDP-bound (inactive) states would regulate ARL1's interactions with effector proteins and consequent cellular functions.

The regulatory significance of this GTP-binding cycle is supported by experimental evidence showing that:

• An allele of ARL1 predicted to be unbound to nucleotide in vivo can complement the hygromycin-B-sensitive phenotype of arl1 mutants, suggesting complex regulation beyond simple GTP binding .

• ARL1's roles in membrane trafficking, ion homeostasis, and vacuole formation likely depend on proper regulation of its GTP-binding state .

Research methodologies to investigate this cycle would include creating point mutations in the GTP-binding domain, analyzing how these affect ARL1's cellular functions, and identifying regulatory proteins that might function as guanine nucleotide exchange factors (GEFs) or GTPase-activating proteins (GAPs) for ARL1.

What methodological approaches are most effective for purifying recombinant ARL1 for structural and functional studies?

Based on research practices in the field, the following methodology would be recommended for purifying recombinant ARL1:

• Expression system selection: A bacterial expression system (E. coli) with a fusion tag (His, GST, or MBP) would typically yield sufficient quantities of protein for biochemical studies.

• Construct design considerations:

  • Include the complete coding sequence with appropriate affinity tags

  • Consider whether to maintain the N-terminal myristoylation site or replace it with a tag

  • For structural studies, removing flexible regions may improve crystallization success

• Purification protocol:

  • Initial capture via affinity chromatography using the fusion tag

  • Intermediate purification using ion exchange chromatography

  • Final polishing step with size exclusion chromatography

  • Include GTP or non-hydrolyzable GTP analogs in buffers if studying the GTP-bound state

• Quality control assessments:

  • Verify nucleotide binding capability using fluorescent GTP analogs

  • Confirm proper folding with circular dichroism spectroscopy

  • Assess oligomeric state via analytical ultracentrifugation

  • Validate functional activity through in vitro assays

This methodological approach provides a systematic framework for obtaining pure, active ARL1 protein suitable for downstream structural and functional analyses.

What roles does ARL1 play in membrane trafficking within yeast cells?

ARL1 functions as a critical regulator of membrane traffic in Saccharomyces cerevisiae . Experimental evidence from arl1Δ strains demonstrates several membrane trafficking defects:

• Reduced protein secretion: arl1Δ strains secrete less protein as measured by TCA-precipitable radioactivity in the media of [35S]-labelled cells .

• Vacuolar protein missorting: A portion of newly synthesized carboxypeptidase Y (CPY) is secreted rather than correctly targeted to the vacuole in arl1Δ strains .

• Impaired endocytosis: Uptake of the fluid-phase marker lucifer yellow is reduced in arl1Δ strains .

• Synthetic interactions with vesicular transport regulators: The temperature-sensitive phenotype of arl1Δ ssd1 strains is suppressed by YPT1 (the yeast Rab1a homologue), suggesting partially overlapping functions in membrane traffic regulation .

• Vacuole formation defects: Mutation in ARL1 (dlp2) leads to the formation of many small vesicles instead of large central vacuoles, indicating a role in vacuole biogenesis through proper membrane trafficking .

The phenotypes of arl1 mutants are often exacerbated in an ssd1 background, highlighting the genetic context dependency of ARL1 function in membrane trafficking pathways .

How does ARL1 contribute to ion homeostasis and cellular stress responses?

ARL1 plays a crucial role in maintaining ion homeostasis in yeast cells, particularly in regulating potassium influx. Research demonstrates that:

• Cation sensitivity: The arl1 mutant exhibits hypersensitivity to various toxic cations, including:

  • Hygromycin B and other aminoglycoside antibiotics

  • Tetramethylammonium ions

  • Methylammonium ions

  • Protons (reflected in pH sensitivity)

  • Ca2+ and Zn2+

• Potassium uptake regulation: The arl1 strain takes up 30-40% less 86Rb+ (a radioactive potassium analog) than wild type cells, indicating defective K+ import regulation .

• Membrane polarization effects: The arl1 mutant internalizes ~25% more [14C]-methylammonium ion than wild type, consistent with hyperpolarization of the plasma membrane, likely resulting from defective K+ import .

• Pathway interactions: The hygromycin-B-sensitive phenotype is:

  • Suppressed by the inclusion of K+ in growth media

  • Complemented by wild-type ARL1 and an allele predicted to be unbound to nucleotide in vivo

• Genetic suppressor analysis: High-copy suppressors of the hygromycin-B phenotype include:

  • SAP155, encoding a protein that interacts with cell cycle regulator Sit4p

  • HAL4 and HAL5, encoding Ser/Thr kinases that regulate K+-influx mediators Trk1p and Trk2p

This evidence suggests ARL1 functions in a regulatory network governing K+ homeostasis, possibly by modulating the activity of potassium transport systems, which in turn affects membrane potential and sensitivity to toxic cations.

What is the relationship between ARL1 and programmed cell death in yeast?

ARL1 plays a significant role in the progression of programmed cell death in yeast, particularly in autophagic cell death pathways. Key research findings include:

• Delay of autophagic death: A recessive mutation in ARL1 (identified as dlp2) delays the progression toward autophagic death in cdc28 cells incubated at restrictive temperatures .

• Vacuole formation defects: The cdc28 dlp2 cells contain many small vesicles instead of the large central vacuoles typically found in parental cdc28 cells, indicating that ARL1 is essential for proper vacuole formation .

• Cellular morphology changes: After a shift to restrictive temperature, the components of the cytoplasm and nucleus of cdc28 dlp2 cells become condensed, with accompanying formation of vesicles in the cell periphery (epiplasm) rather than activation of normal autophagic machinery .

• Impact on Bax-induced cell death: Introducing the ARL1 mutation into wild-type W303 strain inhibits the progression of apoptotic cell death induced by the proapoptotic protein Bax, again due to defects in vacuole formation .

• Evolutionary significance: These findings suggest the presence of a programmed cell death machinery in yeast that is similar to Type II cell death (characterized by autophagocytosis) in mammalian cells .

This research establishes ARL1 as an important factor in the execution of programmed cell death in yeast, specifically through its role in vacuole formation, which appears to be a prerequisite for normal progression of autophagic cell death.

Experimental Design and Methodological Approaches

Several experimental assays have been developed to assess membrane trafficking defects in arl1 mutants:

• Protein secretion assay:

  • Methodology: Cells are labeled with [35S]-methionine/cysteine, and secreted proteins are precipitated from media using TCA.

  • Measurement: Quantification of total secreted radioactivity provides a measure of general secretory pathway function.

  • Application: arl1Δ strains have been shown to secrete less protein than wild-type cells using this assay .

• CPY sorting assay:

  • Methodology: Track the localization and processing of carboxypeptidase Y (CPY), which normally traffics from the ER through the Golgi to the vacuole.

  • Measurement: Detection of CPY in the culture medium (using antibodies or metabolic labeling) indicates missorting.

  • Application: In arl1Δ strains, a portion of newly synthesized CPY is secreted rather than correctly targeted to the vacuole .

• Fluid-phase endocytosis assay:

  • Methodology: Cells are incubated with lucifer yellow, a fluorescent marker that enters cells via fluid-phase endocytosis.

  • Measurement: Fluorescence microscopy and/or quantitative measurement of internalized dye.

  • Application: arl1Δ strains show reduced uptake of lucifer yellow .

• Ion sensitivity tests:

  • Methodology: Serial dilutions of cells are spotted on media containing various toxic cations.

  • Measurement: Growth inhibition indicates defects in ion homeostasis potentially linked to membrane trafficking.

  • Application: arl1 mutants show increased sensitivity to hygromycin B, Ca2+, Zn2+, and other cations .

• Vacuolar morphology analysis:

  • Methodology: Vacuoles are visualized using specific dyes (e.g., FM4-64) or fluorescent proteins targeted to the vacuole.

  • Measurement: Microscopic examination of vacuole size, number, and morphology.

  • Application: arl1 mutants (dlp2) show many small vesicles instead of large central vacuoles .

These assays collectively provide a comprehensive toolkit for characterizing the various aspects of membrane trafficking affected by ARL1 dysfunction.

How can researchers effectively analyze ARL1 protein interactions and post-translational modifications?

To investigate ARL1 protein interactions and post-translational modifications, researchers should consider the following methodological approaches:

• Protein interaction analysis:

  • Yeast two-hybrid screening: Useful for identifying novel protein interactors of ARL1

  • Co-immunoprecipitation: Verifies interactions in native cellular contexts

  • GST pull-down assays: With recombinant ARL1 to test direct binding in vitro

  • Proximity labeling methods: BioID or APEX2 fusions to identify proximal proteins in vivo

  • GTP-dependent interaction studies: Compare interactors in GTP-bound vs. GDP-bound states

• Post-translational modification analysis:

  • N-myristoylation assessment: Metabolic labeling with [3H]-myristic acid to verify N-terminal myristoylation

  • Mass spectrometry: For comprehensive identification of multiple modification types

  • Mutagenesis of putative modification sites: To determine functional significance

  • Subcellular fractionation: To evaluate how modifications affect membrane association

  • In vitro modification assays: Testing ARL1 as a substrate for purified modifying enzymes

• Structure-function analysis:

  • Domain mapping: Creating truncation constructs to determine functional domains

  • Point mutations: Targeting conserved residues to identify critical functional sites

  • Chimeric protein analysis: Swapping domains between ARL1 and other ARLs/ARFs

  • Nuclear magnetic resonance (NMR) or X-ray crystallography: For detailed structural information

• Nucleotide binding and hydrolysis analysis:

  • GTP binding assays: Using radiolabeled or fluorescent GTP analogs

  • GTPase activity measurement: Quantifying inorganic phosphate release

  • Nucleotide exchange assays: To identify potential guanine nucleotide exchange factors

By combining these methodologies, researchers can build a comprehensive understanding of ARL1's interaction network, modification status, and how these factors influence its cellular functions.

How can insights from yeast ARL1 research be translated to understanding human ARL1 function and disease?

Research on Saccharomyces cerevisiae ARL1 provides valuable insights that can be translated to understanding human ARL1 function and disease mechanisms:

• Evolutionary conservation: The high sequence identity (>60%) between yeast and human ARL1 proteins suggests conserved fundamental functions . Anti-yeast ARL1 antibodies react with human ARLs, further confirming structural conservation .

• Membrane trafficking insights: Given ARL1's role in yeast membrane trafficking , human ARL1 may similarly regulate vesicular transport pathways. Dysfunction in these pathways is implicated in various human diseases:

  • Neurodegenerative disorders (Alzheimer's, Parkinson's)

  • Lysosomal storage diseases

  • Certain forms of cancer with aberrant protein trafficking

• Ion homeostasis relevance: Yeast ARL1's function in K+ regulation suggests human ARL1 might influence ion channel activity or regulation. This could be relevant to:

  • Channelopathies

  • Cardiac arrhythmias

  • Neurological disorders with ion imbalances

• Programmed cell death connections: The role of yeast ARL1 in autophagic cell death indicates human ARL1 might participate in autophagy regulation, which is implicated in:

  • Cancer (both tumor suppression and promotion)

  • Neurodegenerative diseases

  • Inflammatory disorders

  • Aging processes

• Methodological translation: Experimental approaches developed in yeast can be adapted for human cell studies:

  • CRISPR/Cas9 gene editing to create ARL1 mutations analogous to yeast mutants

  • Trafficking assays measuring similar cellular processes

  • Proteomic approaches to identify human ARL1 interactors

The simplicity of the yeast system allows for rapid genetic manipulation and comprehensive phenotypic analysis, providing hypotheses that can be tested in more complex human cellular models.

What are the recommended experimental controls when working with recombinant ARL1 in different expression systems?

When working with recombinant ARL1, researchers should implement the following experimental controls to ensure reliable and interpretable results:

• Expression system controls:

  • Empty vector control: Cells transformed with the expression vector without the ARL1 insert

  • Known protein control: Expression of a well-characterized protein using the same system

  • Wild-type ARL1 control: Essential when studying mutant variants

  • Tag-only control: When using tagged versions, express the tag alone to assess tag-specific effects

• Functional activity controls:

  • GTP binding negative control: Include a known GTP-binding deficient mutant (e.g., S25N)

  • GTPase activity negative control: Include a known GTPase-deficient mutant (e.g., Q71L)

  • Heat-inactivated protein: For enzymatic assays, to distinguish enzyme-dependent from spontaneous reactions

  • Non-myristoylated variant: When studying membrane association, include a G2A mutant that cannot be myristoylated

• Localization study controls:

  • Known organelle markers: Co-expression with established markers for Golgi, ER, vacuole, etc.

  • Brefeldin A treatment: Disrupts Golgi structure to verify Golgi localization

  • Other ARF/ARL family members: To compare localization patterns

  • Cytosolic protein control: For fractionation studies

• Purification quality controls:

  • Size exclusion chromatography: To verify monodispersity and proper oligomeric state

  • Circular dichroism: To confirm proper folding

  • Mass spectrometry: To verify protein identity and assess modifications

  • Dynamic light scattering: To detect aggregation

• Genetic complementation controls:

  • Wild-type ARL1 complementation: In arl1Δ strains to confirm phenotype rescue

  • Cross-species complementation: Testing whether human ARL1 can complement yeast arl1Δ

  • Dosage controls: Testing different expression levels to avoid overexpression artifacts

These controls help establish the specificity of observed effects, rule out system-specific artifacts, and ensure that the recombinant protein faithfully represents the native ARL1's properties.

What future research directions might yield the most significant advances in understanding ARL1 biology?

Several promising research directions could substantially advance our understanding of ARL1 biology:

• Structural biology approaches:

  • High-resolution structures of ARL1 in different nucleotide-bound states

  • Cryo-EM studies of ARL1 in complex with its binding partners

  • Structural analysis of ARL1 membrane association mechanisms

  • Comparison of yeast and human ARL1 structures to identify conserved functional surfaces

• Integrated omics approaches:

  • Proteomics to identify the complete ARL1 interactome under different conditions

  • Lipidomics to examine how ARL1 affects membrane composition

  • Transcriptomics to identify genes regulated downstream of ARL1 signaling

  • Metabolomics to assess broader cellular impacts of ARL1 dysfunction

• Advanced imaging technologies:

  • Super-resolution microscopy to visualize ARL1-mediated membrane trafficking events

  • Live-cell imaging with optogenetic control of ARL1 activity

  • Single-molecule tracking to analyze ARL1 dynamics in living cells

  • Correlative light and electron microscopy to link ARL1 localization with ultrastructural features

• Systems biology integration:

  • Network analysis of ARL1 genetic and physical interactions

  • Mathematical modeling of ARL1's role in membrane trafficking pathways

  • Integration of yeast and human datasets to identify conserved regulatory networks

  • Multi-organism comparative analysis to identify evolutionary trends

• Translational research extensions:

  • CRISPR screens to identify synthetic lethal interactions with ARL1 in cancer cells

  • Investigation of ARL1's role in specialized cell types with intensive membrane trafficking (neurons, secretory cells)

  • Examination of ARL1 polymorphisms in human disease cohorts

  • Development of small molecule modulators of ARL1 function for research tools and potential therapeutics

These research directions leverage cutting-edge technologies and interdisciplinary approaches to build a comprehensive understanding of ARL1 biology across evolutionary scales.